Aura Biosciences, Inc. AURA
6.00
(0.15)
(2.44%)
as of 25 Sep
- Market cap
- $637.8M
- P/E
- 0.0×
Follow AURA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
8.15 | 10.77 | 18.76 | 18.81 | 20.90 | 6.94 | 5.42 | — |
Net Debt/EBITDA |
1.29 | 1.59 | 2.70 | 3.19 | 4.33 | 0.81 | 1.37 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.13% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.80 | 0.92 | 0.84 | 0.93 | 0.70 | 0.81 | 0.68 | — |
Capex/Depreciation |
(0.40) | (1.02) | (0.55) | (0.93) | (2.56) | (0.93) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (73.52%) | (46.01%) | (36.26%) | (33.78%) | (211.88%) | 30.73% | 30.83% | — | |
| (60.35%) | (39.73%) | (31.90%) | (30.61%) | (50.72%) | (101.87%) | (163.16%) | — | |
ROIC |
0.00% | (6,857.59%) | 0.00% | (558.12%) | (682.29%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(79.26%) | (58.36%) | (34.33%) | (30.67%) | (30.47%) | (155.58%) | (98.04%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(1.41) | (1.63) | (1.63) | (1.86) | (6.69) | (68.37) | (0.71) | — |
Cash per Share |
2.39 | 3.04 | 5.71 | 6.31 | 28.89 | 47.44 | 1.11 | — |
Shareholders Equity per Share |
2.27 | 3.06 | 5.70 | 6.53 | 29.52 | (296.22) | 1.05 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.27 | 3.06 | 5.70 | 6.53 | 29.52 | (296.22) | 1.05 | — |
Free Cash Flow |
(85.19) | (81.06) | (64.56) | (55.69) | (34.53) | (25.09) | (20.67) | — |
Working Capital |
131.36 | 145.71 | 219.44 | 186.25 | 146.35 | 15.79 | 27.20 | — |
Capital Expenditures |
(0.45) | (1.25) | (0.71) | (1.09) | (2.12) | (0.77) | (2.22) | — |
Net Current Asset Value |
117.22 | 130.09 | 202.57 | 168.35 | 145.99 | (112.36) | 27.05 | — |
| Other line items | ||||||||
Quick Ratio |
7.85 | 10.13 | 18.30 | 18.06 | 20.27 | 6.54 | 5.28 | — |
Depreciation/Fixed assets |
0.43 | 0.38 | 0.41 | 0.22 | 0.16 | 0.23 | 0.14 | — |
Cash ROIC |
(31.07%) | (27.39%) | (14.82%) | (15.60%) | (12.50%) | 30.55% | (38.40%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,672.26 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.40) | (1.61) | (1.61) | (1.82) | (6.28) | (66.27) | (0.71) | — |
Capex per Share |
(0.01) | (0.03) | (0.02) | (0.04) | (0.41) | (2.10) | 0.00 | — |
Average Payables |
1.93 | 2.05 | 2.35 | 2.66 | 1.51 | 1.47 | 1.47 | — |
Average Assets |
175.97 | 218.79 | 239.51 | 191.98 | 91.07 | 29.58 | 18.53 | — |
Average Common Equity |
144.44 | 188.91 | 210.72 | 173.95 | 21.80 | (98.06) | (98.06) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates